Etiology of severe mastitis in French dairy herds.

Severe clinical mastitis is not so frequent in dairy cows, but it can have a significant economic impact due to its high mortality rate and adverse effects on milk production. Surveys about the cause of mastitis typically provide overall findings without connecting them to a specific medical condition. There are few studies on the specific etiology of severe mastitis. Only etiological results obtained during field studies are available in France, and the number of mastitic milk samples analyzed is always low. In recent years, veterinary clinics have improved their ability to identify bacteria causing bovine mastitis using a widely used method. This in-clinic milk culture made it possible to better understand the etiology of mastitis according to the symptoms observed. Regarding clinical mastitis, veterinarians treat severe cases differently than less severe ones. Based on data from nineteen veterinary clinics in France and over 2000 severe mastitis cases, the current study revealed that Enterobacteriaceae, particularly Escherichia coli, is the most common cause, isolated on average from 53.9% of milk samples. This information is highly reliable for practitioners to quickly and effectively treat the condition, because early and targeted treatment is crucial to avoid the complication of endotoxic shock.

Leptospira spp. in Naturally Infected Dairy Cow from a Brazilian Border Region.

Leptospirosis is an important infectious disease, which can generate large economic losses, especially in the dairy herd. The pathogen that causes this disease may have its entry in Brazilian herds facilitated by the existence of a large extension of land borders. Therefore, the objective of this work was to investigate the presence of DNA and antibodies against Leptospira spp. in samples of vaginal mucus and serum from naturally infected bovine females from small rural dairy farms in a border region. Blood and vaginal mucus samples were collected from 70 Holstein cows, from small rural dairy farms between October 2017 and June 2018. The inclusion criteria for dairy cattle of any breed were aged over 2 years, not vaccinated against leptospirosis, and presenting a history of any reproductive problem such as abortion, stillbirth, repetition of heat, absence of heat, and lack of conception. Blood was collected by puncturing the coccygeal vein; for the collection of vaginal mucus, it was necessary to use a tampon with an applicator. For the detection of anti-Leptospira spp. antibodies, the sera were submitted to microscopic agglutination test (MAT) and, for DNA detection, the vaginal mucus was submitted to the PCR technique. Among the 70 cows, 42.86% had reagents in MAT and the most likely serovar was Wolffi (43.47%). In 74.28% of the vaginal mucus samples, it was possible to amplify the Leptospira spp. DNA. The results of this work show the presence of Leptospira spp. antibodies and DNA in samples of serum and vaginal mucus from naturally infected bovine females from small rural dairy farms in a border region (Brazil × Paraguay). These results demonstrate the importance of considering bovine females as potential vaginal carriers of Leptospira spp. Thus, it highlights the importance of further studies to better understanding of this issue, in addition to carrying out molecular and serological tests, to monitor the infection and further characterize epidemiological studies of leptospirosis in herds from regions that face this international frontier challenge.

Assessment of ceftiofur residues in cow milk using commercial screening test kits.

Ceftiofur, a third-generation cephalosporin, is one of the most used antibiotics in dairy industry. Intramuscular injection of 1 mg/kgBW ceftiofur hydrochloride (HCl) generally results in 0 hour withdrawal time for the milk in dairy cows. Nevertheless, farmers and dairy processors occasionally complain about ceftiofur-based products in case of positive result to a commercial rapid screening test for the presence of violative residues of antimicrobials (inhibitors) in the bulk milk tank. Six lactating cows were injected with a 50 mg/ml ceftiofur HCl-based product at the dosage regimen of 1 mg/kg, intramuscularly, once a day, for five consecutive days, as per label. Milk samples were then collected just before the very last injection (T0) and then at 12, 24, 36, 48, 60, 72, 84 and 96 hours after the last injection. Individual milk samples were tested using three commercial screening test kits for inhibitor residues: DelvotestSP NT, SNAP Beta-Lactam ST Plus and ROSA MRL Beta-Lactam Test. Since bulk tank is screened in real operating conditions, samples were also diluted to 1:4, 1:10 and tested again. For the Delvotest SP NT, which lowest detected concentration is close the MRL of the ceftiofur (100 µg/kg), all results were negative. For the ROSA MRL Beta-Lactam Test and the SNAP Beta-Lactam ST Plus, several samples yielded positive and doubtful results at T0 and T12. However, after dilution to 1:10, all results were negative. Consequently, when used as officially instructed, the tested 50 mg/ml ceftiofur HCl-based injectable veterinary products are safe, and milk should be free of violative residues of ceftiofur. With consideration to the low specificity and the low positive predictive value of commercial screening tests, positive reactions of the bulk milk should be interpreted as false positive or another risky usage of ß-lactam-based medicines in the farm must be investigated.

Immune response of mature cows subjected to annual booster vaccination against neonatal calf diarrhoea with two different commercial vaccines: A non-inferiority study.

Neonatal calf diarrhoea can have important economic consequences. Scour vaccines are available against some of the most frequent pathogens responsible for this disease: Bovine Rotavirus (BoRV), Bovine Coronavirus (BoCV) and E. coli K99. In this multi-centre, randomised, blinded study, adult cows vaccinated with a trivalent vaccine marketed for years (Rotavec™ Corona, MSD Animal Health - RC) prior to last parturition were revaccinated 12-15 months later, prior to the upcoming parturition, with either a single injection of a recently marketed vaccine (Bovigen™ Scour, Virbac - BS), or RC. The aim of this trial was to verify whether BS is not inferior to RC for the stimulation of the immune response and the passive transfer to calves in these conditions. A total of 136 multiparous dairy cows, from 5 different herds and located in 3 countries (France, UK and Germany) were enrolled in the study. Sixty-five cows were vaccinated with BS and 71 with RC. Antibody levels, measured by competitive ELISA and represented as percentage of inhibition (PI), were assessed in the cow's serum (on the day of vaccination: D0 and on days 21, 42 and at calving), in the colostrum and in the serum of calves in the first week of life. Differences in means of PI between groups and the 95% confidence interval (CI) were calculated. The non-inferiority threshold was set at -10%. The relationships between antibody levels in the colostrum and the vaccination-calving interval (VCI) or the inter-booster vaccination interval (IBVI) were also analysed. All the lower margins of the 95% CI of the difference in means of PI, in all samples and for the 3 pathogens assessed, were above -10%. This result shows that BS is not inferior to RC for the stimulation of the immune response against BoRV, BoCV and E. coli K99 and the passive transfer of immunity to calves when this vaccine is administered to their dams previously vaccinated with RC. Furthermore, no correlation was found between PI values in the colostrum and the VCI or IBVI. The ratio of animals with a PI ≥ 95% in the colostrum, among cows with similar intervals, was not significantly different between groups, for all antigens tested. Therefore, this study shows that a single injection of the heterologous vaccine BS can be used as a booster in cattle previously vaccinated with RC.

Integrated fly management in European ruminant operations from the perspective of directive 2009/128/EC on sustainable use of pesticides.

Integrated pest management (IPM) in agriculture animals remains undeveloped as compared to IPM in crops. With respect to the range of external nuisance arthropods that may bother farm animals, development and implementation of systematic IPM strategies are difficult to carry out. However, recurrent outbreaks of blue tongue disease in sheep and cattle, the public threats regarding the prophylactic use of veterinary insecticides and the need to preserve the efficacy of available actives have to lead the reflexion on new control strategies for arthropod pests of livestock. A recent extension of EU regulation on the use of pesticides in crops provides an opportunity to compare IPM strategies and to suggest new lines of reflection for the control of nuisance pests in ruminants under European conditions. In this paper, actions suggested by the Annex III of the Directive 2009/128/CE on Sustainable Use of Pesticides and related National Action Plans from 28 member states of the EU were reviewed from an animal production perspective by a group of veterinary entomologists. Eight lines of action have been identified and thus challenged with respect to current husbandry practices in modern European ruminant operations. Many IPM strategies for crops were identified to be unsuitable for large animals. Suggestions for implementing tools, opportunities and constraint assessment, and needs for support were also discussed. Only control of pest development sites and monitoring of harmful organisms were considered achievable in the near future; both in conjunction with the use of topical insecticides. Complementary actions such as alternatives to chemical control require further researches and industrial development. Marketing of IGR-based feed additives would be of great interest, but development of new compounds for veterinary medicines is very unlikely with respect to the European regulatory environment and associated cost of development.